Literature DB >> 22527322

Ranibizumab is not bevacizumab for retinal vein occlusions.

Roberto Gallego-Pinazo, Rosa Dolz-Marco, Manuel Díaz-Llopis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22527322     DOI： 10.1007/s00417-012-2018-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  7 in total

Review 1.  Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.

Authors:  Taygan Yilmaz; Miguel Cordero-Coma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-27       Impact factor: 3.117

2.  Hemorrhagic Macular Infarction After Intravitreal Bevacizumab for Central Retinal Vein Occlusion.

Authors:  Claudio Furino; Francesco Boscia; Nicola Cardascia; Giovanni Alessio; Carlo Sborgia
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2010-03-09

3.  Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.

Authors:  Shunsuke Yasuda; Mineo Kondo; Shu Kachi; Yasuki Ito; Takayuki Terui; Shinji Ueno; Hiroko Terasaki
Journal:  Retina       Date:  2011-06       Impact factor: 4.256

4.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2011-08       Impact factor: 12.079

Review 5.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Authors:  C H Meyer; F G Holz
Journal:  Eye (Lond)       Date:  2011-04-01       Impact factor: 3.775

6.  Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?

Authors:  Joaquin Marticorena; Mario R Romano; Heinrich Heimann; Theodore Stappler; Kurshid Gibran; Carl Groenewald; Ian Pearce; David Wong
Journal:  Br J Ophthalmol       Date:  2010-08-07       Impact factor: 4.638

7.  Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.

Authors:  Yoko Matsumoto; K Bailey Freund; Enrico Peiretti; Michael J Cooney; Daniela C A C Ferrara; Lawrence A Yannuzzi
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256
  7 in total
  1 in total

1.  Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study).

Authors:  Matus Rehak; Eric Tilgner; Annegret Franke; Franziska G Rauscher; Oana Brosteanu; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-18       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.